← Trials/Trial dossier/NCT03500484
Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.
Lead sponsor
Asset
Liraglutide
Subcutaneous · GLP-1 agonist
Listed sites
1
Recruiting sites
—
Enrollment
13
actual
Study population
Healthy volunteers, Obesity / overweight
Key I/E criterion
•BMI 18.5-24.9
Primary endpoint
•Brain Response in Obese Young Adults Who Drink Sugar Sweetened Beverages
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
1. 18-39 years old
2. Lean (BMI 18.5-24.9 kg/m2) with normoglycemia
3. Obese (BMI 30-45 kg/m2) with or without prediabetes
4. Weight stable
5. Right handed
6. Able to read and write in English
7. Able to provide written and verbal informed consent
Exclusion criteria
1. Current active participation in a weight loss program or weight loss of >=10% of total body weight during the previous 6 months
2. Prior bariatric surgery or current gastric balloon
3. Weight >440lbs or waist circumference >142cm
4. Following a vegetarian/vegan diet or dieting/restricting food
5. Significant medical condition
6. Current use of weight-loss medications or supplements, psychiatric medications or anti- hyperglycemic medications
7. History of or family history of multiple endocrine neoplasia type 1 (MEN-I) or medullary thyroid cancer, alcoholism, or previous history of pancreatitis
8. Females who are pregnant or lactating, or who are unwilling to use proper contraception or remain abstinent,
9. Claustrophobia that would interfere with MRI or metal in their body that would pose a risk in the MRI.
Endpoints (6)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Glycemic / diabetes
2 endpointsTo Investigate the Role of Specific Metabolic/Hormonal Responses in the Setting of Liraglutide Treatment, in Affecting Neural Responses to Sugar Ingestion.
Time frame:1 week and 12 weeks
HOMA-IR (insulin sensitivity)
change from baseline, improvement
To Investigate the Role of Specific Metabolic/Hormonal Responses in the Setting of Liraglutide Treatment, in Affecting Neural Responses to Sugar Ingestion.
Time frame:1 week and 12 weeks
HOMA-IR (insulin sensitivity)
change from baseline, improvement
Posted result
| Group | Value (mean), Index | 95% CI |
|---|---|---|
| Participants With Obesity1 Week | 3.54 | — |
| 12 Weeks | 4.08 | — |
Other clinical outcomes
4 endpointsBrain Response in Obese Young Adults Who Drink Sugar Sweetened Beverages.
Time frame:1 week
categorical status, descriptive
Posted result
| Group | Value (count_of_participants), Participants | 95% CI |
|---|---|---|
| Participants With Obesity | 8 | — |
| 0 | — | |
| Participants Who Are Lean | 0 | — |
| 5 | — |
Change in Brain Response in Obese Young Adults Who Drink Sugar Sweetened Beverages.
Time frame:1 week and 12 weeks
categorical status, improvement
Posted result
| Group | Value (count_of_participants), Participants | 95% CI |
|---|---|---|
| Participants With ObesityIncreased blood flow in thalamus at 1 week | 0 | — |
| Increased blood flow in thalamus at 12 weeks | 4 | — |
Brain Response in Obese Young Adults Who Drink Sugar Sweetened Beverages.
Time frame:1 week
categorical status, descriptive
Change in Brain Response in Obese Young Adults Who Drink Sugar Sweetened Beverages.
Time frame:1 week and 12 weeks
categorical status, improvement
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.